Brainstorm cell therapeutics appoints bob dagher, m.d., as executive vice president and chief development officer

Dr. dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases new york , july 12, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of bob dagher, md, as executive vice president and chief development officer effective july 17, 2023. dr. dagher will serve on brainstorm's executive leadership team reporting to stacy lindborg, ph.d.
BCLI Ratings Summary
BCLI Quant Ranking